

Table S1. Information of primary hepatocytes

Donor No.	Viability and yield	Plateability and confluence	Donor demographics		
			Physical	Serology	Medical/social history
AKB	94%; post-thaw viability by trypan blue exclusion 8.76 million viable cells	0.412 OD MTT value and 90% confluent monolayer at day 5	Age: 39 Gender: Female Race: Caucasian	HBV: Neg HCV: Neg HIV: Neg	Hypertension × 3yrs-no compliant; ETOH: Occasionally; Tobacco: 1/2ppd×10yrs; Drug: abused Rx narcotic, smoked marijuana
VHB	86%; post-thaw viability by trypan blue exclusion 8.3 million viable cells	0.271 OD MTT value and 80% confluent monolayer at day 5	Age: 57 Gender: Female Race: Caucasian	HBV: Neg HCV: Neg HIV: Neg	Hypertension × 0-5yrs; ETOH: social; Tobacco: ex-smoker× 1yr; No drug use
XSM	93%; post-thaw viability by trypan blue exclusion 8.37 million viable cells	0.325 OD MTT value and 97% confluent monolayer at day 5	Age: 59 Gender: Female Race: Hispanic	HBV: Neg HCV: Neg HIV: Neg	ETOH: no reported; Tobacco: 1ppd×40yrs; No drug use

Table S2. siRNA sequence

Name	sense(5'-3')
ENT1-a-siENT1	ACCAAGUUGGACCUCAUUA
ENT1-b-siENT1	ACCAAUGAAAGCCACUCUA
NC	UUCUCCGAACGUGUCACGU

Table S3. Transition, fragmentor and collision energy of compounds

Compound	Transition (m/z)	Fragmentor (V)	Collision Energy(eV)
ETV	278/152	110	11
Ribavirin	245/113	70	3
cGMP	346/152	110	16
MPP ⁺	230/112	80	4

Table S4.Primer list for real-time PCR

	Gene	Forward primer (5'-3')	Reverse primer (5'-3')
Human	ENT1	CCTGGCTTTCTCTGTCTGCT	AGTAACGTTCCCAGGTGCTG
	ENT2	CCCTGGATCTTGACCTGGAG	GGTTTTCTGGCTTCTGGG
	OAT2	CTAGACCTGTTCCGCACACCA	CACATCCAGACTCAGGCCGTA
	P-gp	GAAATTTAGAAGATCTGATGTCAAACA	ACTGTAATAATAGGCATACCTGGTCA
	BCRP	CCACTCCCCTGAGATTGAGA	TGCGTTCCTAAATCCTACCC
	MRP2	AGTGAATGACATCTTCACGTTTG	CTTGCAAAGGAGATCAGCAA
	MRP4	GAAGCGCCTGGAATCTACAA	AGAGCCCCTGGAGAGAAGAT
	GAPDH	GCACCGTCAAGGCTGAGAAC	TGGTGAAGACGCCAGTGGA
Mouse	Ent1	GACGGAATTCTATCGCCATT	TCCTTTTGGCTCCTCTCCTT
	Ent2	GCTGTCTCAGGCTCCAATC	GATGGGAACCCCATCTTCT
	Oat2	CAGAATTCTTCCACCATTGC	CAGACAAGTATCCGTACACCACA
	Oct3	TTCGGCTGGCAGCTATATG	CACAGACAGACGCCAGGAT
	P-gp	GGGCATTTACTTCAAACCTTGTC	TTTACAAGCTTCATTTCTAATTCAA
	Bcrp	GCCTTGGAGTACTTTGCATCA	AAATCCGCAGGGTTGTTGTA
	Mrp2	TTTCCTGGATTACCTCCAACC	GCCGAGCAGAAGACAATCA
	Mrp4	TGAAGCAACTGCAAATGTGG	TGTGAGCAATGGTGAGCACT
Gapdh	GAGACAGCCGCATCTTCTTGT	CACACCGACCTTCACCATTTT	